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Abstract
Introduction: In a recent screening to detect biomarkers in systemic lupus erythematosus (SLE), expression of the
iron storage protein, ferritin, was increased. Given that proteins that regulate the storage, transfer and release of
iron play an important role in inflammation, this study aims to determine the serum and urine levels of ferritin and
of the iron transfer protein, transferrin, in lupus patients and to correlate these levels with disease activity,
inflammatory cytokine levels and markers of anemia.
Methods: A protein array was utilized to measure ferritin expression in the urine and serum of SLE patients and
healthy controls. To confirm these results as well as the role of the iron transfer pathway in SLE, ELISAs were
performed to measure ferritin and transferrin levels in inactive or active SLE patients and healthy controls. The
relationship between ferritin/transferrin levels and inflammatory markers and anemia was next analyzed.
Results: Protein array results showed elevated ferritin levels in the serum and urine of lupus patients as compared
to controls, which were further validated by ELISA. Increased ferritin levels correlated with measures of disease
activity and anemia as well as inflammatory cytokine titers. Though active SLE patients had elevated urine
transferrin, serum transferrin was reduced.
Conclusion: Urine ferritin and transferrin levels are elevated significantly in SLE patients and correlate with disease
activity, bolstering previous reports. Most importantly, these changes correlated with the inflammatory state of the
patients and anemia of chronic disease. Taken together, altered iron handling, inflammation and anemia of chronic
disease constitute an ominous triad in SLE.
Introduction
In an effort to identify novel markers of disease activity
in systemic lupus erythematosus (SLE), we recently
compared serum and urine samples from SLE patients
against that of healthy controls, using glass-slide array-
based screens. One of the several molecules that were
elevated in SLE was ferritin. Given the previous implica-
tion of ferritin and other iron-binding proteins (that is,
transferrin and hepcidin) in SLE, we pursued this
increase further to gauge its clinical significance and
possible mechanistic origins.
Ferritin is an acute-phase reactant and is thus elevated
in inflammation, autoimmune disorders, chronic infec-
tion and liver disease. Elevated levels of ferritin are well
established in adult onset Still’s disease (AOSD) [1],
multiple sclerosis (MS) [2], and in both synovial fluid
[3] and synovial cells [4] of rheumatoid arthritis (RA)
patients. In RA patients, association between elevated
levels of serum ferritin and disease activity score (DAS
28) has previously been reported [5]. High concentra-
tions of serum ferritin levels have been reported in
patients with active SLE as compared to inactive SLE
[6-8]. Elevated levels of urinary ferritin have also been
reported in lupus nephritis (LN) patients [9].
Beyond its role as an acute phase protein, ferritin plays
an important role in iron storage and recycling. Ferritin
stores iron in a non-toxic and soluble form and releases
it in a controlled fashion. Ferritin consists of a unique
nanocage structure that resembles a spherical virus and
can store up to 4,500 Fe (III) atoms. Ferritin without the
associated iron is known as apo-ferritin. Apo-ferritin
consists of 24 polypeptide chains of two subunits each: a
heavy sub unit (H) and a light subunit (L). The H subunit
is involved in iron transport, while the L subunit is
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responsible for long-term storage of iron in the liver and
spleen [10]. In addition to iron storage, another impor-
tant function of ferritin in humans is its role in macro-
phages where it recycles iron from old red blood cells
(RBCs) and transfers it to apo-ferritin. The iron in trans-
ferrin is delivered to immature red blood cells in the
bone marrow, thus completing the cycle. Maintaining the
balance of iron is crucial at the organism level, and the
main function of ferritin is in iron homeostasis and sto-
rage of intracellular labile iron [11]. It has been reported
that homozygous murine knockouts of ferritin heavy
chain are lethal [12].
Ferritin also plays an important role in host immune
response as is evident from its increased concentration
during infection in order to counter infective agents that
attempt to bind iron from the host tissue [13]. An
increased immune response augments the migration of
ferritin from the plasma to within the cells, so that iron is
not available to the infective agent. Two key factors that
can regulate ferritin expression are iron [14] and pro-
inflammatory cytokines [15,16]. In this study, we assesed
the clinical relevance of elevated iron-binding proteins in
SLE, and explored their molecular associations.
Materials and methods
Patients
Patients were recruited from the renal clinic at Parkland
Hospital, an affiliated hospital of the University of Texas
Southwestern Medical Center at Dallas. All patient-
related procedures were performed strictly following the
institutionally approved IRB protocol (UT Southwestern,
#STU 082010-119). All patient informed consents were
obtained prior to sample collection. Five SLE patients
were used for a pilot study using the screening protein
array, as described below in the section on protein array.
Validation studies were performed using serum and
urine samples from an independent cohort of SLE
patients using an orthogonal method. All lupus patients
fulfill the American College of Rheumatology (ACR) cri-
teria for the diagnosis of SLE. Serum samples were col-
lected from 28 SLE patients. Urine samples were
collected from 27 SLE patients, of whom 16 provided
both urine and serum. Detailed clinical information is
summarized in Table 1.
Protein array
The serum samples used for the initial array-based
screen were from three healthy individuals (mean age,
52; three females, 2AA + 1H) and five patients with SLE
(mean age, 33.4; five females, 3AA + 2H; three with
active renal disease with SLE disease activity index (SLE-
DAI) ≥ 10 and renal-related SLE disease activity index
(rSLEDAI) ≥ 8). The urine samples used for the initial
array-based screen were from three healthy individuals
(mean age, 35; three females), and five patients with LN
(mean age, 38.3; four females + one male; mean SLEDAI
= 19.4; mean rSLEDAI = 9.6). These serum and urine
samples were hybridized to glass-slide arrays that inter-
rogate the levels of 274 different human proteins (Ray-
biotech, Norcross, GA, USA).
Validation assay
Serum and urine samples obtained from the renal clinic
at Parkland Hospital were aliquoted prior to storage at
-80°C, and only one aliquot was retrieved for each assay
to avoid multiple freeze/thaw cycles. Urine and serum
ferritin were measured using a precoated human ferritin
ELISA kit from Raybiotech, Inc. Urine and serum trans-
ferrin were measured using a human transferrin ELISA
kit from Genway Biotech (San Diego, CA, USA). Urine
creatinine was measured using a creatinine assay kit
from Cayman Chemical (Ann Arbor, MI, USA). Urinary
ferritin and urinary transferrin levels were normalized
against urine creatinine. Urine and serum cytokines,
Table 1 Demographics and clinical characteristics of




Female, no. (%) 25 (89.3) 21 (77.8)








Renal SLEDAI, median (interquartile) 5 (0 to 8) 5 (0 to 8)
No. of patients with renal SLEDAI = 0 (%) 10 (35.7) 9 (33.3)
Protein:creatinine ratio, mg/mg, mean +/- SE 2.0 ± 0.5 2.3 ± 0.5
Serum Cr, mg/dl, mean +/- SE 1.3 ± 0.2 1.4 ± 0.2
Comorbidities, no. (%)
Diabetes Melitus 3 (10.7) 4 (14.8)
Hypertension 20 (71.4) 20 (74.1)
Dyslipidemia 12 (42.8) 15 (55.6)
Cardiovascular disease 4 (14.3) 3 (11.1)
Anemia 16 (57.1) 18 (66.7)
Antiphospholipid syndrome 3 (10.7) 3 (11.1)
Venous thromboembolism 3 (10.7) 3 (11.1)
Others 14 (50%) 11 (40.7)
Current medications, no. (%)
Prednisone 17 (60.7) 20 (74)
Mycophenolic acid 7 (25) 7 (25.9)
Cyclophosphamide 1 (3.6) 2 (7.4)
Azathioprine/MTX 6 (21.4) 3 (11.1)
Cyclosporine/Tacrolimus 2 (7.1) 1 (3.7)
Hydrochloroquine 12 (42.9) 11 (40.7)
Angiotensin blocking agents 14 (50) 16 (59.3)
1Note that 16 SLE patients had provided both serum and urine samples.
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such as IL-1a, IL-6 and TNF-a, were measured using a
Bio-Plex Pro™ Assay kit (Bio-Rad, Hercules, CA, USA),
following the manufacturer’s instructions.
Statistics
Data were plotted and analyzed using Graphpad Prism 5
(GraphPad, San Diego, CA, USA). A T-test was used
where the normality test passed; otherwise, the nonpara-
metric Mann-Whitney test was used to analyze the data.
Likewise, the Pearson method or the nonparametric
Spearman method was used for correlation analysis.
Results
Increased ferritin levels in SLE
In an effort to identify novel biomarkers in SLE, sera
and urine samples from SLE patients were compared to
that of healthy controls using arrays that interrogate 274
different analytes. One of the molecules that was up-
regulated in SLE was ferritin (Figure 1). While the
increased ferritin levels in SLE patient sera (N = 5) mea-
sured by this array were not statistically significant (P =
0.155), urine ferritin levels were significantly increased
(P = 0.020) in LN patients compared to healthy controls.
Next, to validate the array results, serum samples from
healthy, inactive SLE and active SLE patients were
examined for ferritin levels using ELISA. Ferritin levels
were increased significantly (P = 0.013) in the sera of
active SLE patients as compared to the inactive SLE
group. Although SLE patients exhibited elevated serum
ferritin (median = 1,058) compared to healthy controls
(median = 825), these differences were not statistically
significant, possibly due to the raised levels of serum
ferritin in one healthy individual (Figure 2).
To determine if increased ferritin expression was
related to increased disease activity, serum ferritin titers
in SLE patients were compared against SLEDAI scores,
serum creatinine concentration and various urine analy-
sis parameters. Serum ferritin levels correlated signifi-
cantly with SLEDAI (R = 0.56, P = 0.001), serum
creatinine (R = 0.54, P = 0.001), and urine RBC count
(R = 0.58, P < 0.001) (Figure 2).
To validate the array findings with the urine samples,
urine from healthy, inactive SLE and active SLE patients
were examined for ferritin levels by ELISA. Ferritin levels
were significantly increased in active (P < 0.001) and inac-
tive SLE patients (P = 0.03) when compared with healthy
controls. There was a significant increase in ferritin levels
in the active SLE patients as compared to those with inac-
tive SLE (P = 0.02). To determine if increased ferritin
expression was related to increased disease severity, urine
ferritin levels were next compared against various clinical
parameters. Urine ferritin/creatinine (Cr) levels correlated
with urine protein/Cr levels (R = 0.43, P = 0.013), SLEDAI
(R = 0.26, P = 0.096), and serum complement (C3/C4)
(R = 0.31, P = 0.067) (Figure 3).
Increased ferritin expression in SLE correlates with
increased transferrin expression
Given that transferrin is another iron-binding protein
that has been reported to be altered in SLE [17], we
asked if these patients also exhibited elevated transferrin
levels. Serum and urine samples of active and inactive
SLE patients and healthy controls were analyzed for
transferrin levels by ELISA. Urine transferrin levels were
significantly increased in active and inactive SLE patients
when compared with healthy controls. Also, transferrin
Figure 1 Serum and urine ferritin levels are increased in patients with lupus. Ferritin levels in serum and urine of healthy (N = 3), SLE (N =
5) and LN (N = 5) patients were determined using a protein array (Raybiotech, Norcross, GA, USA). Serum ferritin levels were increased by 2.5-
fold in SLE patients as compared to healthy controls, and the expression was 18.7-fold higher in the urine of LN patients compared to healthy
controls. An unpaired Student’s t-test with Welch’s correction was applied to compare the means between groups. Data represent the mean ±
standard error of mean (SEM). * represents P = 0.02.
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levels were raised in inactive SLE patients when com-
pared with controls. Elevated urine transferrin/Cr levels
correlated significantly with urine ferritin levels (R =
0.46, P = 0.005), SLEDAI scores (R = 0.42, P = 0.033),
and rSLEDAI (R = 0.49, P = 0.013) (Figure 4). In contrast
to urine transferrin, serum transferrin levels were in fact
lower in active SLE patients (Figure 4D).
Correlation of elevated ferritin levels with inflammation
and anemia in SLE
In light of the previous reports that inflammatory cyto-
kines may regulate ferritin expression [15,16], we further
examined whether the patients with elevated ferritin
levels also had elevated levels of inflammatory cytokines,
using the data from the original array-based screening.
Serum and urine ferritin levels of healthy (N = 3), SLE
(N = 5), and LN patients (N = 5), as measured by the
protein arrays, were analyzed for possible correlation
with serum levels of interleukin (IL)-1a, IL-6, and
tumor necrosis factor (TNF)a, also interrogated on the
same arrays. Urine ferritin levels correlated significantly
with urine IL-6 (P < 0.001, Figure 5 and Additional
file 1), and with TNF-a (P = 0.02, Additional file 1, and
IL-1a (P = 0.07, Additional file 1). Although the serum
ferritin levels exhibited similar trends, these correlations
did not attain statistical significance. Interestingly,
serum and urine ferritin levels in SLE patients also cor-
related with anemia, as marked by the reduced hemo-
globin and hematocrit (Figure 6).
Discussion
The present study reveals urinary elevations in two key
iron-binding proteins (ferritin and transferrin) in SLE
patients, the levels of which were found to be correlated
with each other, as well as with disease activity, inflam-
matory status and anemia. Collectively, this constellation
of abnormalities may serve as a marker of disease sever-
ity in SLE.
Previously, Shoenfeld and coworkers provided evidence
for hyperferritinemia in lupus [18,19], where it was sug-
gested to be a biomarker in lupus. Specifically, hyperferriti-
nemia was associated with thrombocytopenia, lupus
anticoagulant and anti-cardiolipin antibodies, suggesting
that it may be an early marker of antiphospholipid syn-
drome in SLE [18]. Likewise, in a Japanese population,
Nishiya et al. demonstrated elevated levels of serum ferri-
tin in SLE patients as compared to RA patients and also
reported that these increased levels positively correlated
with SLEDAI and negatively with complement levels [6].
Another study by Beyan et al. showed a similar rise in
serum ferritin levels in Turkish SLE patients and a signifi-
cant change in ferritin levels before and after treatment,
and also showed a positive correlation between serum fer-
ritin levels and SLEDAI [8]. A study of a Korean cluster of
SLE patients by Lim et al. also suggested similar results
and indicated the use of ferritin as a marker of disease
activity in SLE patients [7]. However, these studies did not
relate the change in ferritin levels to inflammation or
Figure 2 ELISA analysis of serum ferritin and its correlation
with disease activity and serum creatinine levels. Ferritin levels
in serum of healthy (N = 9), inactive SLE (N = 10), and active SLE (N
= 18) patients were determined by ELISA (Raybiotech, Norcross, GA,
USA). Serum ferritin levels were increased 6.3-fold in active SLE
patients compared to healthy controls and 9.8-fold higher in active
SLE patients (P = 0.014) when compared with inactive SLE patients.
Serum ferritin levels correlated significantly with SLEDAI scores (R =
0.56, P = 0.001) and serum creatinine levels (R = 0.54, P = 0.001).
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anemia. The present study is the first of its kind to be con-
ducted in African American, Hispanic and Caucasian SLE
patients. Our results demonstrate a significantly positive
and linear correlation of serum ferritin levels with SLE-
DAI, serum creatinine levels and urine RBC counts, and a
weaker correlation with serum complement. This study,
along with previous reports by other groups, indicates that
if the basal levels of ferritin in SLE patients are known, a
significant variation in these levels can be used as a reliable
indicator of disease activity. Given recent studies showing
that increased serum ferritin levels are associated with
increased risk of atherosclerotic coronary artery disease
(CAD) and myocardial infarction [20], serum ferritin may
also be useful in tracking CAD, a leading cause of morbid-
ity and mortality in SLE.
As has been previously reported for urinary ferritin
levels in LN [9], our study demonstrates a significant
increase in urinary ferritin levels (normalized against
urinary creatinine) in active SLE, as detected using an
ELISA- and protein array-based approach. Furthermore,
urinary ferritin levels showed a positive correlation with
urinary protein/Cr levels, and a negative correlation
with levels of serum complement (C3/C4).
Ferritin synthesis is regulated by intracellular iron at
both the transcriptional and translational levels. When
iron levels are low, ferritin synthesis is reduced and vice
versa. Ferritin regulation by iron is largely posttranscrip-
tional [14]. The 5’ end of the heavy and light chain ferri-
tin mRNA contains an iron responsive element (IRE)
that has a stem-loop structure. RNA-binding proteins,
Figure 3 ELISA analysis of urine ferritin and its correlation with disease activity, urine protein/Cr levels, and complement levels. Ferritin
levels in urine of healthy (N = 9), inactive SLE (N = 10), and active SLE (N = 17) patients were determined by ELISA (Raybiotech, Norcross, GA,
USA). Expression of ferritin in the urine of active SLE patients were increased 12-fold as compared to healthy controls (P < 0.001), and by 3-fold
as compared to inactive SLE patients (P = 0.02). Ferritin expression was 4-fold higher in inactive SLE patients as compared to healthy controls (P
= 0.03). Data represent the mean ± SEM. Urine ferritin/Cr levels correlated significantly with urine protein/Cr levels (R = 0.43, P = 0.013), with
SLEDAI (R = 0.25, P = 0.096), and with serum C3/C4 levels (R = 0.301, P = 0.067).
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Figure 4 ELISA analysis of urine and serum transferrin levels. Transferrin levels in urine of healthy controls (N = 10), inactive SLE (N = 10)
and active SLE (N = 10) patients were measured by ELISA (Genway Biotech, San Diego, CA, USA). Transferrin expression was increased by 87-fold
(P = 0.002) in active SLE patients compared with healthy controls, and by 14-fold (P = 0.003) when compared with inactive SLE patients. Urine
transferrin/UCr levels correlated significantly with urine ferritin/Cr levels (R = 0.45, P = 0.005), disease activity, (R = 0.41, P = 0.033), and SLEDAI (R
= 0.418, P = 0.033). Data represent mean ± SEM.
Figure 5 Correlation of serum and urine ferritin levels with inflammatory cytokine levels. Serum and urine ferritin levels determined using
ELISA were correlated with inflammatory cytokine levels. Urine ferritin levels correlated with urine IL-6 (r = 0.68, P < 0.001) and serum IL-6 (r =
0.56, P < 0.0001).
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known as iron regulatory proteins IRP1 and IRP2, bind to
this stem loop structure and inhibit the translation of fer-
ritin mRNA, with different tissue-specific roles [21-23].
The positive correlation between serum ferritin levels
and proinflammatory cytokines observed in our study is
supported by a number of reports in the literature. The
proinflammatory cytokines, TNFa and IL-1a, are known
to stimulate the expression of ferritin by inducing the
transcription of the H ferritin gene in mouse adipocytes
and human muscle cells [15]. Also, translation of ferritin
is induced by IL-6, TNFa and IL-1a in the HepG2
hepatic cell line [16], and iron is essential for this regu-
lation as the fact that the upregulation of ferritin is
inhibited by deferoxamine [24]. Cytokines indirectly reg-
ulate ferritin translation by inducing synthesis of nitric
oxide synthase, which in turn increases nitric oxide
(NO), an activator of both IRP1 and IRP2 [25]. Lipopo-
lysaccharides (LPS), a component of the outer mem-
brane of gram-negative bacteria elicit a number of
reactions that involve ferritin. Although LPS is known
to stimulate a number of inflammatory cytokines, there
are reports where endotracheal administration of LPS in
rats increased ferritin mRNA expression [26]. Ferritin is
also regulated by oxidative stress directly by targeting
specific genes or indirectly by the modification of IRPs.
In mouse models, the macrophage is the main source
of serum ferritin [27]. During immune responses, acti-
vated macrophages produce more ferritin, which results
in elevated serum ferritin in the circulation. Human
CD4+ and CD8+ T lymphocytes and CD19+ B lympho-
cytes express H-ferritin binding sites, which are posi-
tively associated with the proliferative status of these
Figure 6 Correlation of serum and urine ferritin with hematocrit (Hct) and hemoglobin (Hgb). Serum and urine ferritin levels measured by
ELISA were correlated with Hct and Hgb. Serum ferritin correlated negatively with Hct (R = -0.42, P = 0.012) and Hgb (R = -0.47, P = 0.006). Urine
ferritin levels also correlated negatively with Hct (R = -0.37, P = 0.028) and Hgb (R = -0.25, P = 0.110), although the correlation with Hgb was
comparatively weaker.
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immune cells [28]. In ferritin treated mice, clonal expan-
sion and maturation of precursor T cells into effector T
cells was suppressed, suggesting that ferritin has immu-
nosuppressive effects on lymphocyte proliferation [29].
Both L- and H-rich ferritin exert their inhibitory activity
on immunoglobulin generation by B cells in a T-inde-
pendent as well as T-dependent way [28]. The immuno-
suppressive effects of ferritin may be mediated by IL-10
production from regulatory T cells [30]. Patients with
rheumatoid arthritis (RA) have higher concentrations of
free iron and lactoferrin, the latter may play a role in
preventing toxic damage to the synovium from free iron
which accumulates during the inflammatory response
[31].
Taken together with the above mechanistic studies,
our findings suggest that inflammation in SLE is likely
to be a major driving force in up-regulating ferritin
expression. Inflammation is also well established to up-
regulate hepcidin-mediated degradation of the iron
transport channel, ferroportin, thereby sequestering iron
in the form of ferritin in the cells of reticulo endothelial
system. This results in the unavailability of iron for Hb
production, hence explaining the anemia. A further fea-
ture of “anemia of chronic inflammation” is raised ferri-
tin coupled with reduced transferrin, a scenario
witnessed in our present study.
It is instructive to reconsider the salient differences
between iron deficiency anemia and anemia of chronic
disease. Iron-deficiency anemia and ‘anemia of chronic
disease’ both exhibit reduced serum iron but are very
different otherwise. Whereas anemia of chronic disease
is marked by elevated ferritin but reduced transferrin
(and total iron-binding capacity (TIBC)) levels, iron defi-
ciency anemia exhibits the reverse profile. Indeed, the
SLE patients described in this report exhibit ‘anemia of
chronic disease’ rather than iron deficiency anemia. One
could certainly further demonstrate this by examining
bone marrow iron stores (increased in chronic inflam-
mation but depleted in iron-deficiency anemia), but this
is beyond the scope of this report. Given that most SLE
patients with anemia have anemia of chronic disease
rather than iron-deficiency anemia, it is important to
manage this accordingly in the clinics. Targeting the
underlying inflammation rather than treating it with
iron supplements may be a more fruitful approach in
these patients.
There are several caveats of note in the present study.
As discussed above, examination of iron stores in the
bone marrow could further substantiate the presence of
“anemia of chronic disease” in SLE. Since the current
studies are cross-sectional in nature, we do not yet
know if the markers described in this report truly have
disease-predictive value. Future longitudinal studies are
clearly warranted to test the predictive potential of these
markers in SLE. In addition, further studies will be
needed to understand the impact of medications on fer-
ritin levels, and the impact of ferritin on the ongoing
autoimmune process. Finally, one needs to explore if
anemia of chronic disease is also a prominent feature of
other chronic diatheses, including RA.
In conclusion, we have established a positive linear
correlation between ferritin levels in SLE and disease
activity, thus bolstering previous reports in other ethnic
groups. Most importantly, the changes in ferritin and
transferrin levels correlated with the inflammatory state
and anemia in SLE, making them potential markers of
disease activity. Taken together, inflammation ® ele-
vated ferritin ® “anemia of chronic inflammation” may
constitute an ominous triad in SLE.
Conclusions
Urinary ferritin and transferrin levels are increased sig-
nificantly in SLE patients and correlated with disease
activity, supporting previous reports in other ethnic
groups. Most importantly, the elevation of ferritin and
transferrin correlated with the inflammatory state and
anemia of chronic disease suggesting that hyperferritine-
mia could potentially play a role in regulating immunity.
Taken together, altered iron handling, inflammation and
anemia of chronic disease may constitute an ominous
triad in SLE.
Additional material
Additional file 1: Figure S1. Correlation of serum and urine ferritin
levels with inflammatory cytokine levels. Serum and urine ferritin
levels determined by using a protein array were correlated with cytokine
levels measured in the same assay. Urine ferritin levels correlated with IL-
6 (R = 0.94, P < 0.001), TNF a (R = 0.71, P = 0.022), and IL-1a (P = 0.073).
Serum ferritin levels showed weaker correlations with proinflammatory
cytokine levels.
Abbreviations
ACR: American College of Rheumatology; AOSD: adult onset Still’s disease;
CAD: coronary artery disease; Cr: creatinine; DAS 28: Disease Activity Score
28; IRE: iron responsive element; LN: lupus nephritis; LPS: lipopolysaccharide;
MS: multiple sclerosis; NO: nitric oxide; RA: rheumatoid arthritis; rSLEDAI:
renal-related SLE disease activity index; SLE: systemic lupus erythematosus;
SLEDAI: SLE disease activity index; TIBC: total iron-binding capacity; TNF:
tumor necrosis factor.
Acknowledgements
We acknowledge the financial support of this study from the NIH.
Authors’ contributions
TW and CM conceived of the study, designed the study and drafted the
manuscript. KV, YY, JH and TW carried out the screening and validation
studies, and performed the statistical analysis. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Vanarsa et al. Arthritis Research & Therapy 2012, 14:R182
http://arthritis-research.com/content/14/4/R182
Page 8 of 9
Received: 13 December 2011 Revised: 25 July 2012
Accepted: 7 August 2012 Published: 7 August 2012
References
1. Uppal SS, Al-Mutairi M, Hayat S, Abraham M, Malaviya A: Ten years of
clinical experience with adult onset Still’s disease: is the outcome
improving? Clin Rheumatol 2007, 26:1055-1060.
2. Da Costa R, Szyper-Kravitz M, Szekanecz Z, Csepany T, Danko K, Shapira Y,
Zandman-Goddard G, Orbach H, Agmon-Levin N, Shoenfeld Y: Ferritin and
prolactin levels in multiple sclerosis. Isr Med Assoc J 2011, 13:91-95.
3. Blake DR, Bacon PA, Eastham EJ, Brigham K: Synovial fluid ferritin in
rheumatoid arthritis. Br Med J 1980, 281:715-716.
4. Muirden KD: Ferritin in synovial cells in patients with rheumatoid
arthritis. Ann Rheum Dis 1966, 25:387-401.
5. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K:
Associations between acute phase reactant levels and disease activity
score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci
2004, 34:423-426.
6. Nishiya K, Hashimoto K: Elevation of serum ferritin levels as a marker for
active systemic lupus erythematosus. Clin Exp Rheumatol 1997, 15:39-44.
7. Lim MK, Lee CK, Ju YS, Cho YS, Lee RS, Yoo B, Moon HB: Serum ferritin as
a serologic marker of activity in systemic lupus erythematosus.
Rheumatol Int 2001, 20:89-93.
8. Beyan E, Beyan C, Demirezer A, Ertugrul E, Uzuner A: The relationship
between serum ferritin levels and disease activity in systemic lupus
erythematosus. Scand J Rheumatol 2003, 32:225-228.
9. Nishiya K, Kawabata F, Ota Z: Elevated urinary ferritin in lupus nephritis.
J Rheumatol 1989, 16:1513-1514.
10. Theil EC: Ferritin: structure, gene regulation, and cellular function in
animals, plants, and microorganisms. Annu Rev Biochem 1987, 56:289-315.
11. Picard V, Epsztejn S, Santambrogio P, Cabantchik ZI, Beaumont C: Role of
ferritin in the control of the labile iron pool in murine erythroleukemia
cells. J Biol Chem 1998, 273:15382-15386.
12. Ferreira C, Bucchini D, Martin ME, Levi S, Arosio P, Grandchamp B,
Beaumont C: Early embryonic lethality of H ferritin gene deletion in
mice. J Biol Chem 2000, 275:3021-3024.
13. Chow JK, Werner BG, Ruthazer R, Snydman DR: Increased serum iron levels
and infectious complications after liver transplantation. Clin Infect Dis
2010, 51:E16-E23.
14. Torti FM, Torti SV: Regulation of ferritin genes and protein. Blood 2002,
99:3505-3516.
15. Torti SV, Kwak EL, Miller SC, Miller LL, Ringold GM, Myambo KB, Young AP,
Torti FM: The molecular cloning and characterization of murine ferritin
heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem 1988,
263:12638-12644.
16. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P: Differential effects of
cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4
in human hepatocytes in primary culture. Hepatology 1995, 22:1143-1153.
17. Rovin BH, Zhang X: Biomarkers for lupus nephritis: the quest continues.
Clin J Am Soc Nephrol 2009, 4:1858-1865.
18. Zandman-Goddard G, Orbach H, Agmon-Levin N, Boaz M, Amital H,
Szekanecz Z, Szucs G, Rovensky J, Kiss E, Corocher N, Doria A, Stojanovich L,
Ingegnoli F, Meroni PL, Rozman B, Gomez-Arbesu J, Blank M, Shoenfeld Y:
Hyperferritinemia is associated with serologic antiphospholipid
syndrome in SLE patients. Clin Rev Allergy Immunol 2011.
19. Zandman-Goddard G, Peeva E, Shoenfeld Y: Gender and autoimmunity.
Autoimmun Rev 2007, 6:366-372.
20. You SA, Wang Q: Ferritin in atherosclerosis. Clin Chim Acta 2005, 357:1-16.
21. Thomson AM, Rogers JT, Leedman PJ: Iron-regulatory proteins, iron-
responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol
1999, 31:1139-1152.
22. Eisenstein RS: Iron regulatory proteins and the molecular control of
mammalian iron metabolism. Annu Rev Nutr 2000, 20:627-662.
23. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E,
Drake SK, Miller G, Abu-Asab M, Tsokos M, Switzer R, Grinberg A, Love P,
Tresser N, Rouault TA: Targeted deletion of the gene encoding iron
regulatory protein-2 causes misregulation of iron metabolism and
neurodegenerative disease in mice. Nat Genet 2001, 27:209-214.
24. Hirayama M, Kohgo Y, Kondo H, Shintani N, Fujikawa K, Sasaki K, Kato J,
Niitsu Y: Regulation of iron metabolism in HepG2 cells: a possible role
for cytokines in the hepatic deposition of iron. Hepatology 1993,
18:874-880.
25. Weiss G, Goossen B, Doppler W, Fuchs D, Pantopoulos K, Werner-
Felmayer G, Wachter H, Hentze MW: Translational regulation via iron-
responsive elements by the nitric oxide/NO-synthase pathway. EMBO J
1993, 12:3651-3657.
26. Carraway MS, Ghio AJ, Taylor JL, Piantadosi CA: Induction of ferritin and
heme oxygenase-1 by endotoxin in the lung. Am J Physiol 1998, 275:
L583-592.
27. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL,
Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ,
Rouault TA, Meyron-Holtz EG: Serum ferritin is derived primarily from
macrophages through a nonclassical secretory pathway. Blood 2010,
116:1574-1584.
28. Morikawa K, Oseko F, Morikawa S: A role for ferritin in hematopoiesis and
the immune system. Leuk Lymphoma 1995, 18:429-433.
29. Harada T, Baba M, Torii I, Morikawa S: Ferritin selectively suppresses
delayed-type hypersensitivity responses at induction or effector phase.
Cell Immunol 1987, 109:75-88.
30. Gray CP, Arosio P, Hersey P: Heavy chain ferritin activates regulatory T
cells by induction of changes in dendritic cells. Blood 2002, 99:3326-3334.
31. Baker JF, Ghio AJ: Iron homoeostasis in rheumatic disease. Rheumatology
(Oxford) 2009, 48:1339-1344.
doi:10.1186/ar4012
Cite this article as: Vanarsa et al.: Inflammation associated anemia and
ferritin as disease markers in SLE. Arthritis Research & Therapy 2012 14:
R182.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vanarsa et al. Arthritis Research & Therapy 2012, 14:R182
http://arthritis-research.com/content/14/4/R182
Page 9 of 9
